Tyme Technologies GAAP EPS of -$0.03
- Tyme Technologies press release (NASDAQ:TYME): FQ3 GAAP EPS of -$0.03.
- The company is on track for mid-2022 full enrollment of HopES trial for SM-88 used in patients with high-risk Ewing’s and other sarcoma types.